1 August
2023
4basebio
PLC
("4basebio", the "Company"
or the "Group")
4basebio receives grant to
advance its synthetic DNA platform and Hermes™ nanoparticle
platform for the development of
thermostable nucleic acid
vaccines
-
Funding from the Bill
& Melinda Gates Foundation will build on preclinical data
demonstrating superior immune responses achieved with 4basebio's
synthetic DNA products as well as improved stability offered by its
Hermes™
platform.
Cambridge, UK, 1 August
2023 - 4basebio PLC (AIM: 4BB), an innovation driven
biotechnology company enabling and accelerating development of
advanced therapy medicinal products (ATMPs) through its high
performant synthetic DNA products and non-viral, thermostable
nucleic acid delivery platform, today announces it has received a
grant from the Bill & Melinda Gates Foundation (the
"Foundation") to advance the development program of thermostable
nucleic acid based vaccines.
The development program
aims to build on preclinical data demonstrating the improved
stability offered by the Hermes™ platform, the superior immune
responses achieved with 4basebio's synthetic DNA products and
high-quality mRNA produced from 4basebio opDNA™
products.
The successful
demonstration of the Hermes™ platform and 4basebio synthetic
nucleic acid payloads in infectious disease vaccines has the
potential to enhance the global availability of such innovative
medicines.
Heikki Lanckriet, CEO and CSO of 4basebio,
commented: "The Foundation's
grant recognises the potential of our Hermes™ and synthetic DNA
platforms. The enhanced stability offered by our vectors as well as
the rapid turnaround time offered through our synthetic DNA has the
potential to enable a faster response to pandemic needs and create
highly performant and affordable vaccine products in support of the
global fight against infectious
diseases."
For further enquiries,
please contact:
4basebio
PLC
+44 (0)12 2396 7943
Heikki
Lanckriet
Nominated
Adviser
+44 (0)20 7213 0880
Cairn
Financial Advisers
LLP
Jo Tuner / Sandy
Jamieson
Broker
+44 (0)20 7220 0500
finnCap
Ltd
Geoff Nash/Richard
Chambers/Charlotte
Sutcliffe
Lionsgate Communications
(Media
Enquiries)
+44 (0)77 91892509
Jonathan
Charles
Notes
to Editors
About
4basebio
4basebio (AIM: 4BB)
is an innovation driven life biotechnology company focussed on
accelerating the development of advanced therapy medicinal products
(ATMPs) through its high performant synthetic DNA products and
non-viral, cell targeting nucleic acid delivery platform. The
Company's objective is to become a market leader in the manufacture
and supply of high quality synthetic DNA products for research,
therapeutic and pharmacological use as well as development of
target specific non-viral vectors for the efficient delivery of
payloads in patients. The Company is offering GMP compliant DNA
starting materials suitable for use in AAV viral vector production
as well as mRNA vaccine and therapeutics
production.
Forward-looking
statements
This announcement may
contain certain statements about the future outlook for the
4basebio. Although the directors believe their expectations
are based on reasonable assumptions, any statements about future
outlook may be influenced by factors that could cause actual
outcomes and results to be materially
different.